1. Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.
- Author
-
Kitazawa S, Chiyoda T, Nakamura K, Sakai K, Yoshihama T, Nishio H, Kobayashi Y, Iwata T, Banno K, Yamagami W, Nishihara H, and Aoki D
- Subjects
- Humans, Female, Biomarkers, Tumor genetics, Mutation, Genital Neoplasms, Female pathology, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms drug therapy, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Sarcoma
- Abstract
Background: Japan's health insurance covers multigene panel testing. This study aimed to determine the potential availability and utility of gene panel testing clinically in gynecologic oncology., Methods: We analyzed the characteristics of patients with gynecologic cancer who underwent gene panel testing using FoundationOne
® CDx or OncoGuide™ NCC Oncopanel between November 2019 and October 2022., Results: Out of 102 patients analyzed, 32, 18, 43, 8, and 1 had cervical, endometrial, ovarian cancers, sarcoma, and vaginal cancer, respectively. Druggable gene alteration was found in 70 patients (68.6%; 21 with cervical cancer, 15 with endometrial cancer, 28 with ovarian cancer, 5 with sarcoma, and 1 with other). The most common druggable gene alteration was PIK3CA mutation (n = 21), followed by PTEN mutation (n = 12) and high tumor mutation burden (TMB-H) (n = 11). TMB-H was detected in 5 patients with cervical cancer, 5 with endometrial cancer, and 1 with endometrial stromal sarcoma. Eleven patients (10.8%) received molecularly targeted therapy according to their gene aberrations. Gene panel testing was mostly performed when the second-line treatment was ineffective. Of all 102 patients, 60 did not have recommended treatment, and 15 died or had worsened conditions before obtaining the test results., Conclusion: Through multigene panel testing, although many patients had druggable gene alterations, 10.8% of them received the recommended treatment. TMB-H was mainly observed in cervical/endometrial cancer, suggesting its potential as a therapeutic biomarker of immune checkpoint inhibitors. Furthermore, patients' prognosis and performance status should be considered before performing the test., (© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)- Published
- 2023
- Full Text
- View/download PDF